ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,575.90
-1.39%
S&P ASX All Technology
2,970.40
-1.25%
Brent Oil
88.165
0.02%
US Dollar vs AUD
1.53139
-0.11%
Bitcoin
63,747.54
-1.14%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Merck and Co Inc (MRK)

  7. Merck and Co Inc (MRK) News

MRK Merck and Co Inc

130.96
0.24 (0.18%)
After Hours
Last Updated: 07:13:59
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Merck and Co Inc MRK NYSE Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.24 0.18% 130.96 07:13:59
Open Price Low Price High Price Close Price Previous Close
130.13 130.13 131.91 131.20 130.72
more quote information »

Recent News

Date Time Source Heading
26/4/202406:40IHMARKETNEWSU.S. Stocks Climb Well Off Worst Levels But Close Mostly..
25/4/202423:09IHMARKETNEWSFutures Pointing To Sharply Lower Open On Wall Street
25/4/202421:52IHMARKETNEWSSouthwest Shares Tumble 9.6% Post $231 Million 1Q Loss,..
25/4/202420:30BWMerck Announces First-Quarter 2024 Financial Results
19/4/202421:04PRNCAHealth Canada Approves KEYTRUDA® as a first-line treatment..
10/4/202421:13IHMARKETNEWSDelta Generates US$37 Million Profit in Q1, Google and Intel..
04/4/202421:45BWMerck Initiates Phase 3 Clinical Trial of MK-1084, an..
03/4/202423:00BWREJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan..
01/4/202421:45BWMerck to Hold First-Quarter 2024 Sales and Earnings..
28/3/202421:45BWEuropean Commission Approves Merck’s KEYTRUDA®..
27/3/202421:54IHMARKETNEWSGameStop Shares Tumble 20% in Pre-Market Trading Amid..
27/3/202409:21BWFDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a..
21/3/202421:45BWMerck Provides Update on Phase 3 KEYLYNK-006 Trial..
20/3/202400:00BWMerck Announces Positive Data on V116, an Investigational,..
16/3/202407:23PRNUSFarmSee Ltd Announces the Completion of a Minority..
15/3/202421:45BWMerck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy..
13/3/202418:00BWMerck Announces Plans to Conduct Clinical Trials of a Novel..
11/3/202423:15BWMerck Completes Acquisition of Harpoon Therapeutics, Inc.
07/3/202402:25BWGilead and Merck Announce Phase 2 Data Showing an..
06/3/202401:03IHMARKETNEWSFutures Pointing To Continued Weakness On Wall Street
05/3/202422:45BWMerck to Participate in the Barclays 26th Annual Global..
04/3/202422:45BWMerck to Participate in the Leerink Partners Global..
27/2/202422:45BWMerck to Participate in the TD Cowen 44th Annual Health Care..
23/2/202422:20BWMerck Receives Positive EU CHMP Opinion for KEYTRUDA®..
21/2/202408:14EDGAR2Form 8-K - Current report
20/2/202422:45BWFDA Grants Priority Review to Merck's Application for..
16/2/202408:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202408:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202408:40EDGAR2Form 144 - Report of proposed sale of securities
15/2/202408:30EDGAR2Form 144 - Report of proposed sale of securities
15/2/202408:24EDGAR2Form 144 - Report of proposed sale of securities
14/2/202408:50EDGAR2Form 144 - Report of proposed sale of securities
14/2/202408:48EDGAR2Form 144 - Report of proposed sale of securities
13/2/202408:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202423:05PRNCAHealth Canada Approves KEYTRUDA® in combination with..
10/2/202408:06EDGAR2Form 144 - Report of proposed sale of securities
09/2/202408:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/2/202423:00PRNCAMERCK CANADA ANNONCE UNE COLLABORATION AVEC L'INSTITUT..
08/2/202408:09EDGAR2Form 144 - Report of proposed sale of securities
06/2/202408:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202422:33PRNUSElanco Announces Sale of Aqua Business for $1.3 Billion
03/2/202408:35EDGAR2Form 144 - Report of proposed sale of securities
03/2/202408:09EDGAR2Form 144 - Report of proposed sale of securities
03/2/202408:08EDGAR2Form 144 - Report of proposed sale of securities
03/2/202408:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/2/202408:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202422:39EDGAR2Form 8-K - Current report
01/2/202422:30BWMerck Announces Fourth-Quarter and Full-Year 2023 Financial..
28/1/202402:00BWMerck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death..
27/1/202403:49EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..

Your Recent History

NYSE
MRK
Merck
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved